Research programme: cancer therapeutics - DepYmed
Alternative Names: Cu chelating cancer therapeutics - DepYmedLatest Information Update: 04 Nov 2020
At a glance
- Originator DepYmed
- Class Antineoplastics
- Mechanism of Action Chelating agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Triple negative breast cancer
Most Recent Events
- 28 Oct 2020 Preclinical trials in Triple negative Breast cancer in USA (unspecified route) prior to October 2020 (DepYmed pipeline, October 2020)